

Postgraduate course Programme

Precision Management of Severe Infections and Sepsis: from Translational Research to Clinical Practice

Athens, Greece
25 - 27 September 2024



Precision Management of Severe Infections and Sepsis: from Translational Research to Clinical Practice

Athens, Greece



Faculty Members

France	Djillali Annane
Turkey	Emine Alp Meşe
Spain	Antonio Artigas
Germany	Michael Bauer
Italy	Matteo Bassetti
Germany	Krista Bracke
Greece	Eirini Christaki
Germany	Christian Eckmann
Greece	George Dimopoulos
Greece	Evangelos J. Giamarellos-Bourboulis
Belgium	Maya Hites
Greece	Eleni Karakike
Greece	Evdoxia Kyriazopoulou
France	Brigitte Lamy
Italy	Rita Murri
Greece	Garyphalia Poulakou
Netherlands	W. Joost Wiersinga

Precision Management of Severe Infections and Sepsis: from Translational Research to Clinical Practice

Athens, Greece



Day 1 Wednesday, 25 September 2024

08:45 – 09:00	Opening comments and learning objectives E. J. Giamarellos-Bourboulis and M. Bassetti
SESSION 1: PRECISION ANTIMICROBIAL TREATMENT Chair: D. Annane	
09:00 – 09:30	Why are we in need of this approach? G. Poulakou
09:30 – 10:00	The burden of carbapenem-resistant Enterobacterales M. Hites
10:00 – 10:30	Use of biomarkers to guide treatment E. Kyriazopoulou
10:30 – 11:00	Round table discussion with speakers
11:00 – 11:30	Break
SESSION 2: HOW TO DEAL WITH RESISTANCE (Part I) Chair: M. Bassetti	
11:30 – 12:00	New drugs: main properties R. Murri
12:00 - 12:30	Inhibition of carbapenemases: does this really work? M. Bassetti
12:30 - 13:00	Carbapenem-resistant <i>Acinetobacter baumannii</i>: are there real options? G. Poulakou
13:00 – 13:30	Is there room for empirical prescription? R. Murri
13:30 – 14:00	Molecular microbiology to guide prescription B. Lamy
14:00 – 15:00	Lunch
SESSION 2: HOW TO DEAL WITH RESISTANCE (Part II) Chair: M. Bassetti	
15:00 - 15:30	The guidelines M. Hites
15:30 - 16:00	Round table discussion with speakers
INTERACTIVE CASES Tutors: M. Bassetti, B. Lamy, R. Murri, G. Poulakou	
16:00 - 16:30	Interactive case 1
16:30 - 17:00	Interactive case 2
17:00 - 17:30	Interactive case 3

Day 2 **Thursday, 26 September 2024**

SESSION 3: SEPSIS CLASSIFICATION

Chair: A. Artigas

08:30 – 09:00	Sepsis and antimicrobial resistance: the burden and the denominator E. Karakike
09:00 – 09:30	Endotypes and phenotypes W. J. Wiersinga
09:30 – 10:00	Classification using biomarkers D. Annane
10:00 – 10:30	The ARDS paradigm G. Dimopoulos
10:30 – 11:00	Round table discussion with the chairs
11:00 – 11:30	Break
SESSION 4: EARLY RECOGNITION	
Chair: E. Alp Meşe	
11:30 – 12:00	Clinical scoring at the emergency department E. Alp Meşe
12:00 – 12:30	Protein biomarkers for risk assessment: can they help? Eirini Christaki
12:30 – 13:00	Molecular biomarkers W. J. Wiersinga
13:00 – 13:30	Bacterial or viral or both? E. J. Giamarellos-Bourboulis
13:30 – 14:00	Round table discussion with the chairs
14:00 – 15:00	Lunch
SESSION 5: IMMUNOTHERAPY: TO FEAR OR NOT TO FEAR?	
Chair: E. J. Giamarellos-Bourboulis	
15:00 – 15:30	Macrolides: antibiotics or immunomodulators? E. Karakike
15:30 – 16:00	Corticosteroids: a pragmatic approach D. Annane
16:00 – 16:30	Can this harm? An ID perspective E. Kyriazopoulou
16:30 – 17:00	Lessons from the pandemic inside the ICU G. Dimopoulos
17:00 – 17:30	Lessons from the pandemic outside the ICU E. Alp Meşe
17:30 – 18:00	Round table discussion with the speakers

Precision Management of Severe Infections and Sepsis: from Translational Research to Clinical Practice

Athens, Greece



Day 3 Friday, 27 September 2024

SESSION 6: RESEARCH & DEVELOPMENT

Chair B. Lamy

08:30 – 09:00	Towards improved diagnostics B. Lamy
09:00 – 09:30	Source control C. Eckmann
09:30 – 10:00	Cell therapy A. Artigas
10:00 – 10:30	Precision approaches: is it prime time? E. J. Giamarellos-Bourboulis
10:30 – 11:00	What European grants should aim for? M. Bauer
11:00 – 11:30	Round table discussion with the speakers
11:30 – 12:00	Break

SESSION 7: RAISING SEPSIS AWARENESS

Chair: A. Artigas

12:00 – 12:30	Why do we not speak about sepsis? A. Artigas
12:30 – 13:00	Relatives' reactions: the physician perspective Eirini Christaki
13:00 – 13:30	Families suffer K. Bracke
13:30 – 14:00	Skin infections: the threat within C. Eckmann
14:00 – 14:30	How to embark healthy systems M. Bauer
14:30	Closure

Precision Management of Severe Infections and Sepsis: from Translational Research to Clinical Practice

Athens, Greece



INVITED SPEAKERS

- *Djillali Annane* Counselor of the French Minister of Health for Research and Medical Education, Dean of the Faculty of Medicine at the University of Versailles, Head of the critical care department at Raymond Poincaré University Hospital, Garches, Paris, France, Member of the Steering Committee of the European Sepsis Alliance
- *Emine Alp Meşe* Professor of Infectious Diseases, University of Ankara, Turkey
- *Antonio Artigas* Professor of Critical Care Medicine, University of Barcelona, Spain, Member of the Steering Committee of the European Sepsis Alliance, Board member: Global Sepsis Alliance
- *Michael Bauer* Professor and Chairman, Department of Anesthesiology and Critical Care Medicine, Jena University Hospital, Germany
- *Matteo Bassetti* Professor and Chairman, Department of Infectious Diseases, University of Genoa, Italy, Chairman of the Working Group of ESCMID of Infectious in the Critically Ill Patients
- *Krista Bracke* Patient advocacy, European Sepsis Alliance, Italy
- *Christian Eckmann* Professor and Chairman, Department of Surgery, University of Hannover, Germany
- *Eirini Christaki* Assistant Professor of Infectious Diseases, University of Ioannina, Greece
- *George Dimopoulos* Professor and Chairman, 3rd Department of Critical Care Medicine, National and Kapodistrian University of Athens, Medical School, Greece
- *Evangelos J. Giamarellos-Bourboulis* Professor of Internal Medicine and Infectious Diseases, Director: Master (MSc) Program of Infectious Diseases, 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, President: European Sepsis Alliance, Board member: Global Sepsis Alliance, President: Hellenic Institute for the Study of Sepsis, President: Hellenic Society for Chemotherapy
- *Maya Hites* Professor of Infectious Diseases, Erasme University of Brussels, Belgium
- *Eleni Karakike* Consultant, 2nd Department of Critical Care Medicine, National and Kapodistrian University of Athens, Medical School, Greece
- *Evdoxia Kyriazopoulou* Consultant, 2nd Department of Critical Care Medicine, National and Kapodistrian University of Athens, Medical School, Greece
- *Brigitte Lamy* Professor of Bacteriology, University of Nice, France
- *Rita Murri* Professor of Infectious Diseases, Gemelli University of Rome, Italy
- *Garyphalia Poulakou* Associate Professor of Infectious Diseases, 3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Greece, General Secretary: Hellenic Society of Chemotherapy
- *W. Joost Wiersinga* Professor and Chairman, Department of Infectious Diseases, Amsterdam Medical Center, the Netherlands

Precision Management of Severe Infections and Sepsis: from Translational Research to Clinical Practice

Athens, Greece



Congress Secretariat:



IMAGINE CONGRESS & TRAVEL E.E

9 Kolokotroni Str. 105 62 Athens, Greece

Tel: 0030 210 3252520 - Email: info@imaginecongress.gr

Venue: AKISA Building
Of the National and kapodistrian University
Of Athens
ATTIKON University Hospital
1, Rimini street
12462 Athens -Greece

Sponsors and supporters



ΕΛΛΗΝΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΜΕΛΕΤΗΣ ΤΗΣ ΣΗΨΗΣ
HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS



Precision Management of Severe Infections and Sepsis: from Translational Research to Clinical Practice

Athens, Greece



The Organizers of the Postgraduate Course Precision Management of Severe Infections and Sepsis: from Translational Research to Clinical Practice wish to express their gratitude to our supporters:



Menarini Hellas

ThermoFisher
SCIENTIFIC

Love the **SCIENCE** of You

Thermo Fisher Scientific is a proud supporter of the LGBTQ+ community.





TENKASI®

oritavancin

ΤΡΟΠΟΣ ΧΟΡΗΓΗΣΗΣ: Ενδοφλέβια έγχυση (εφάπαξ δόση) διάρκειας 3 ωρών.

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ: Με Ιατρική συνταγή

ΠΕΡΙΕΚΤΙΚΟΤΗΤΑ ΚΑΙ ΣΥΣΚΕΥΑΣΙΑ:

PD.C.SO.IN 400MG/VIAL BT x 3 vials

Καλύπτεται από τα ασφαλιστικά ταμεία.

N.T.: 1.991,68 €

A.T.: 2.418,50 €

ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:

Κάθε φιαλίδιο περιέχει διφωσφορική οριταβανκίνη που ισοδυναμεί με 400 mg οριταβανκίνης. Μετά την ανασύσταση, 1 ml διαλύματος περιέχει 10 mg οριταβανκίνης.

Μετά την αραίωση, 1 ml διαλύματος προς έγχυση περιέχει 1,2 mg οριταβανκίνης. Για τον πλήρη κατάλογο των εκδόχων, βλ. Π.Χ.Π. παράγραφο 6.1.

Πριν τη συνταγογράφηση, για πλήρεις συνταγογραφικές πληροφορίες και πληροφορίες σχετικά με την ασφάλεια και ανεκτικότητα παρακαλούμε συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος [σκανάροντας το QR Code](#).

Για περισσότερες πληροφορίες και για την πλήρη Π.Χ.Π. παρακαλώ απευθυνθείτε στην εταιρεία:



 **Menarini Hellas**

Menarini Hellas A.E. - Πάτμου 16-18, 151 23,
Μαρούσι, Αττική Τ.: 210 8316111-13, F.: 210 8317343,
info@menarini.gr, www.menarini.gr

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και **αναφέρετε ΟΛΕΣ** τις ανεπιθύμητες ενέργειες για **ΟΛΑ** τα φάρμακα συμπληρώνοντας την «**ΚΙΤΡΙΝΗ ΚΑΡΤΑ**»

ZAVICEFTA



ceftazidime and avibactam



Ceftazidime
Avibactam



PRIX GALIEN GREECE
Αθήνα 2019

ΚΑΛΥΤΕΡΟ ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ



Pfizer Ελλάς Α.Ε.,
Λ. Μεσογείων 243, Ν. Ψυχικό 15451, Αθήνα, Ελλάδα,
Τηλ. Επικοινωνίας 210-6785800,
Αριθ. Γ.Ε.ΜΗ. 000242901000
Pfizer Ελλάς Α.Ε. (Cyprus Branch)
Λεωφόρος Αθαλάσσης 26, 2018 Λευκωσία, Κύπρος,
Τηλ : 22817690

Για πλήρεις συνταγογραφικές πληροφορίες συμβουλευτείτε την
Περίληψη Χαρακτηριστικών του Προϊόντος που διατίθεται από την εταιρεία.

**Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»**

